The role of tocilizumab in the treatment of post‐transfusion hyperhaemolysis

Hyperhaemolysis syndrome (HHS) is a serious complication of transfusion mostly reported in patients with sickle cell disease. HHS is characterised by the destruction of both donor and autologous red blood cells. Tocilizumab is a recombinant humanised monoclonal antibody that inhibits the binding of...

Descripción completa

Detalles Bibliográficos
Autores principales: Desai, Naeem, Peters, Jayne, Davies, Elizabeth, Sharif, Joseph
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Short Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10660106/
https://www.ncbi.nlm.nih.gov/pubmed/38024590
http://dx.doi.org/10.1002/jha2.779
Descripción
Sumario:Hyperhaemolysis syndrome (HHS) is a serious complication of transfusion mostly reported in patients with sickle cell disease. HHS is characterised by the destruction of both donor and autologous red blood cells. Tocilizumab is a recombinant humanised monoclonal antibody that inhibits the binding of interleukin‐6 and has been used in the treatment of severe/critical coronavirus disease 2019 infection but also some cases of HHS. We describe two further cases of HHS successfully treated with tocilizumab and propose a decision aid for when to consider this treatment.

Ejemplares similares